Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 12/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066759 | 0.87 | F10 (0.56) | TTRF10HDAC8MRGPRX4 | |
| SCHEMBL6066475 | 0.87 | F10 (0.56) | NR4A2NR4A1NR4A3F10S1PR4 | |
| SCHEMBL6871677 | 0.85 | F10 (0.47) | F10S1PR4 | |
| SCHEMBL6066520 | 0.83 | F10 (0.54) | NR4A2TTRNR4A1NR4A3F10 | |
| SCHEMBL6066505 | 0.81 | HDAC8 (0.56) | NR4A2TTRNR4A1NR4A3F10 | |
| SCHEMBL6066466 | 0.80 | F10 (0.54) | NR4A2TTRF10HDAC8 | |
| SCHEMBL6066381 | 0.79 | F10 (0.60) | TTRF10HDAC8 | |
| SCHEMBL6066651 | 0.79 | F10 (0.55) | NR4A2NR4A1NR4A3F10S1PR4 | |
| SCHEMBL6066439 | 0.78 | NR4A2 (0.58) | NR4A2NR4A1NR4A3F10MRGPRX4 | |
| SCHEMBL5088161 | 0.78 | MRGPRX4 (0.59) | NR4A2TTRNR4A1NR4A3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1228039-B1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| US-6664393-B2 | Anticoagulants | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-16 | — | — | US | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20030162967-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-08-28 | — | — | US | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6472562-B1 | SUCH AS 4-NITRO-N-(1-CARBAMOYL-4-GUANIDINOBUTYL)-3-(2-(2,4 -DICHLOROPHENYL)ETHOXY)BENZAMIDE; ANTITHROMBOTICS; CARDIOVAS-CULAR DISORDERS LIKE THROMBOEMBOLICS OR RESTENOSES; REVERSI-BLE INHIBITORS OF BLOOD CLOTTING ENZYMES FACTOR XA, VIIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| EP-1228039-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001032611-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
| EP-1095933-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162967-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | F7, GUCY1A2, F9 | NR4A2 4617/4885TTR 2014/4885NR4A1 3949/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | NR4A2 4257/4885TTR 2479/4885NR4A1 4057/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | NR4A2 3567/4885TTR 3661/4885NR4A1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.